Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Sep 13, 2024
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ardelyx, Inc.
|
0
|
$3.30 | -$161,749.00 |
—
| 1.22M |
Sep 11
| |||||||
Ardelyx, Inc.
| -7.50K |
$6.22 | -$46,635.00 | -0.61% | 1.22M |
Aug 27
|
Scheduled
| ||||||
Ardelyx, Inc.
| -32.23K |
$5.86 | -$188,848.17 | -2.56% | 1.23M |
Aug 20
| |||||||
Ardelyx, Inc.
| -1.23K |
$5.71 | -$7,017.59 | -0.10% | 1.26M |
Aug 12
|
Scheduled
| ||||||
Ardelyx, Inc.
|
0
|
$3.32 | -$139,614.00 |
—
| 1.26M |
Jul 29
|
Scheduled
| ||||||
Ardelyx, Inc.
| -7.50K |
$5.97 | -$44,767.50 | -0.59% | 1.26M |
Jul 15
|
Scheduled
| ||||||
Ardelyx, Inc.
| -2.31K |
$6.59 | -$15,222.90 | -0.18% | 1.27M |
Jun 28
|
Scheduled
| ||||||
Ardelyx, Inc.
|
0
|
$3.82 | -$198,093.00 |
—
| 1.27M |
Jun 13
|
Scheduled
| ||||||
Tempest Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jun 13
| |||||||
Amicus Therapeutics, Inc.
| 11.85K |
—
|
—
| +14.17% | 95.44K |
Jun 6
| |||||||
Ardelyx, Inc.
| -7.50K |
$6.72 | -$50,390.25 | -0.59% | 1.27M |
May 29
|
Scheduled
| ||||||
Ardelyx, Inc.
| -31.48K |
$7.81 | -$245,921.52 | -2.40% | 1.28M |
May 21
| |||||||
Ardelyx, Inc.
| -3.00K |
$7.99 | -$23,970.00 | -0.23% | 1.31M |
May 14
| |||||||
Ardelyx, Inc.
|
0
|
$3.70 | -$162,357.00 |
—
| 1.31M |
Apr 29
| |||||||
Ardelyx, Inc.
| -7.50K |
$7.06 | -$52,923.75 | -0.57% | 1.31M |
Apr 15
| |||||||
Ardelyx, Inc.
| -1.52K |
$7.31 | -$11,096.58 | -0.12% | 1.32M |
Apr 1
| |||||||
Amicus Therapeutics, Inc.
| 15K |
$2.80 | $42,000.00 | +21.87% | 83.6K |
Mar 5
| |||||||
Ardelyx, Inc.
| -22.92K |
$8.75 | -$200,438.96 | -1.71% | 1.32M |
Feb 20
| |||||||
Ardelyx, Inc.
| 475K |
—
|
—
| +54.73% | 1.34M |
Jan 16
| |||||||
Ardelyx, Inc.
| -11.37K |
$4.36 | -$49,589.49 | -1.29% | 867.87K |
Nov 20
| |||||||
Ardelyx, Inc.
| -11.42K |
$3.55 | -$40,558.00 | -1.29% | 876.24K |
Aug 21
| |||||||
Tempest Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jun 15
| |||||||
Amicus Therapeutics, Inc.
| 8.58K |
—
|
—
| +14.30% | 68.6K |
Jun 8
| |||||||
Ardelyx, Inc.
| -11.36K |
$3.65 | -$41,489.39 | -1.26% | 887.65K |
May 23
| |||||||
Amicus Therapeutics, Inc.
| 10.59K |
$7.33 | -$142.64 | +21.43% | 60.01K |
Mar 17
| |||||||
Ardelyx, Inc.
| -13.45K |
$3.00 | -$40,360.45 | -1.48% | 896.01K |
Feb 21
| |||||||
Ardelyx, Inc.
| 250K |
—
|
—
| +37.91% | 909.46K |
Jan 5
| |||||||
Ardelyx, Inc.
| -6.22K |
$1.95 | -$12,120.29 | -0.93% | 659.46K |
Nov 22
| |||||||
Ardelyx, Inc.
| 3K |
$0.62 | $1,856.40 | +0.45% | 665.68K |
Aug 31
| |||||||
Ardelyx, Inc.
| -6.15K |
$0.98 | -$6,045.36 | -0.92% | 662.68K |
Aug 22
| |||||||
Tempest Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jun 17
| |||||||
Amicus Therapeutics, Inc.
| 12.67K |
—
|
—
| +34.48% | 49.42K |
Jun 9
| |||||||
Ardelyx, Inc.
| -103.62K |
$0.65 | -$67,416.27 | -13.41% | 668.83K |
Jun 6
| |||||||
Ardelyx, Inc.
| -6.12K |
$0.67 | -$4,111.65 | -0.79% | 772.45K |
May 20
| |||||||
Amicus Therapeutics, Inc.
|
0
|
$5.89 | -$33,040.50 |
—
| 36.75K |
May 2
|
Scheduled
| ||||||
Ardelyx, Inc.
| -6.23K |
$0.67 | -$4,173.43 | -0.80% | 775.57K |
Feb 22
| |||||||
Ardelyx, Inc.
| 150K |
—
|
—
| +23.74% | 781.8K |
Jan 6
| |||||||
Ardelyx, Inc.
| -2.61K |
$0.99 | -$2,585.88 | -0.41% | 631.8K |
Nov 22
| |||||||
Ardelyx, Inc.
| 300K |
—
|
—
| +89.71% | 634.41K |
Oct 8
| |||||||
Tempest Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Sep 21
| |||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. | |||||||||||||
Want to view more results?
Unlock the hidden results with your Benzinga Account now. No purchase required.